199 related articles for article (PubMed ID: 35593483)
1. Comprehensive genomic profiling in advanced/metastatic colorectal cancer: number needed to test and budget impact of expanded first line use.
Proudman D; DeVito NC; Belinson S; Allo MA; Morris ED; Signorovitch J; Patel AK
J Med Econ; 2022; 25(1):817-825. PubMed ID: 35593483
[TBL] [Abstract][Full Text] [Related]
2. Budget impact analysis of comprehensive genomic profiling in patients with advanced non-small cell lung cancer.
Signorovitch J; Zhou Z; Ryan J; Anhorn R; Chawla A
J Med Econ; 2019 Feb; 22(2):140-150. PubMed ID: 30430885
[TBL] [Abstract][Full Text] [Related]
3. Budget impact analysis of comprehensive genomic profiling for untreated advanced or recurrent solid cancers in Japan.
Tang W; Hanada K; Motoo Y; Sakamaki H; Oda T; Furuta K; Abutani H; Ito S; Tsutani K
J Med Econ; 2023; 26(1):614-626. PubMed ID: 37073487
[TBL] [Abstract][Full Text] [Related]
4. Budget Impact Analysis of Comprehensive Genomic Profiling in Patients With Advanced Non-Small-Cell Lung Cancer.
Harvey MJ; Cunningham R; Sawchyn B; Montesion M; Reddy P; McBride A; Chawla AJ
JCO Precis Oncol; 2021 Nov; 5():1611-1624. PubMed ID: 34994647
[TBL] [Abstract][Full Text] [Related]
5. Cost-Effectiveness of Tumor Genomic Profiling to Guide First-Line Targeted Therapy Selection in Patients With Metastatic Lung Adenocarcinoma.
Dong OM; Poonnen PJ; Winski D; Reed SD; Vashistha V; Bates J; Kelley MJ; Voora D
Value Health; 2022 Apr; 25(4):582-594. PubMed ID: 35365302
[TBL] [Abstract][Full Text] [Related]
6. Tumour mutational burden, microsatellite instability, and actionable alterations in metastatic colorectal cancer: Next-generation sequencing results of TRIBE2 study.
Antoniotti C; Korn WM; Marmorino F; Rossini D; Lonardi S; Masi G; Randon G; Conca V; Boccaccino A; Tomasello G; Passardi A; Swensen J; Ugolini C; Oberley M; Tamburini E; Casagrande M; Domenyuk V; Fontanini G; Giordano M; Abraham J; Spetzler D; Falcone A; Lenz HJ; Cremolini C
Eur J Cancer; 2021 Sep; 155():73-84. PubMed ID: 34365081
[TBL] [Abstract][Full Text] [Related]
7. Effect of a Collaboration Between a Health Plan, Oncology Practice, and Comprehensive Genomic Profiling Company from the Payer Perspective.
Reitsma M; Fox J; Borre PV; Cavanaugh M; Chudnovsky Y; Erlich RL; Gribbin TE; Anhorn R
J Manag Care Spec Pharm; 2019 May; 25(5):601-611. PubMed ID: 30632889
[TBL] [Abstract][Full Text] [Related]
8. Cost of genetic testing, delayed care, and suboptimal treatment associated with polymerase chain reaction versus next-generation sequencing biomarker testing for genomic alterations in metastatic non-small cell lung cancer.
Bestvina CM; Waters D; Morrison L; Emond B; Lafeuille MH; Hilts A; Lefebvre P; He A; Vanderpoel J
J Med Econ; 2024; 27(1):292-303. PubMed ID: 38391239
[TBL] [Abstract][Full Text] [Related]
9. Total cost of testing for genomic alterations associated with next-generation sequencing versus polymerase chain reaction testing strategies among patients with metastatic non-small cell lung cancer.
Vanderpoel J; Stevens AL; Emond B; Lafeuille MH; Hilts A; Lefebvre P; Morrison L
J Med Econ; 2022; 25(1):457-468. PubMed ID: 35289703
[TBL] [Abstract][Full Text] [Related]
10. Comprehensive Genomic Profiling (CGP)-Informed Personalized Molecular Residual Disease (MRD) Detection: An Exploratory Analysis from the PREDATOR Study of Metastatic Colorectal Cancer (mCRC) Patients Undergoing Surgical Resection.
Lonardi S; Nimeiri H; Xu C; Zollinger DR; Madison RW; Fine AD; Gjoerup O; Rasola C; Angerilli V; Sharma S; Wu HT; Palsuledesai CC; Malhotra M; Aleshin A; Loupakis F; Renkonen E; Hegde P; Fassan M
Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232827
[TBL] [Abstract][Full Text] [Related]
11. Budget impact of capmatinib for adults with metastatic non-small cell lung cancer harboring a
Cai B; Zhou ZY; Xue W; Hazra NC; Singh M; Mishra D; Brixner D; Oderda G; Biskupiak J
J Med Econ; 2021; 24(1):131-139. PubMed ID: 33397178
[TBL] [Abstract][Full Text] [Related]
12. Broad Detection of Alterations Predicted to Confer Lack of Benefit From EGFR Antibodies or Sensitivity to Targeted Therapy in Advanced Colorectal Cancer.
Rankin A; Klempner SJ; Erlich R; Sun JX; Grothey A; Fakih M; George TJ; Lee J; Ross JS; Stephens PJ; Miller VA; Ali SM; Schrock AB
Oncologist; 2016 Nov; 21(11):1306-1314. PubMed ID: 27682134
[TBL] [Abstract][Full Text] [Related]
13. [Questionnaire Survey on the Timing of Comprehensive Genomic Profiling for Advanced Recurrent Colorectal Cancer and Its Impact on Patients].
Yarimizu A; Kuribayashi M; Nomura K; Kimura K; Takenaka Y; Song J; Ohashi E; Nishimura Y; Demachi T; Hirata M; Beppu N; Uchino M; Ikeuchi H; Ikeda M; Kataoka K
Gan To Kagaku Ryoho; 2023 Aug; 50(8):891-893. PubMed ID: 37608415
[TBL] [Abstract][Full Text] [Related]
14. Integrated budget impact model to estimate the impact of introducing selpercatinib as a tumor-agnostic treatment option for patients with
Bhandari NR; Gilligan AM; Myers J; Ale-Ali A; Smolen L
J Med Econ; 2024; 27(1):348-358. PubMed ID: 38334069
[TBL] [Abstract][Full Text] [Related]
15. Budget Impact of Next-Generation Sequencing for Molecular Assessment of Advanced Non-Small Cell Lung Cancer.
Yu TM; Morrison C; Gold EJ; Tradonsky A; Arnold RJG
Value Health; 2018 Nov; 21(11):1278-1285. PubMed ID: 30442274
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Origin: Retrospective Molecular Classification Considering the CUPISCO Study Design.
Ross JS; Sokol ES; Moch H; Mileshkin L; Baciarello G; Losa F; Beringer A; Thomas M; Elvin JA; Ngo N; Jin DX; Krämer A
Oncologist; 2021 Mar; 26(3):e394-e402. PubMed ID: 33219618
[TBL] [Abstract][Full Text] [Related]
17. The budget impact of adding pralsetinib to a US health plan formulary for treatment of non-small cell lung cancer and thyroid cancer with
Duff S; Bargiacchi F; Norregaard C; Brener M; Sullivan E
J Manag Care Spec Pharm; 2022 Feb; 28(2):218-231. PubMed ID: 34726500
[No Abstract] [Full Text] [Related]
18. Cost-effectiveness of pembrolizumab for the first-line treatment of patients with unresectable or metastatic MSI-H/dMMR colorectal cancer in the United States.
Aguiar-Ibáñez R; Hardern C; van Hees F; Lee D; Patel A; Chhabra N; Baluni G; Amonkar M; Lai Y; Xu R; Massaad R; Fogelman D
J Med Econ; 2022; 25(1):469-480. PubMed ID: 35184650
[TBL] [Abstract][Full Text] [Related]
19. Complementary Roles for Tissue- and Blood-Based Comprehensive Genomic Profiling for Detection of Actionable Driver Alterations in Advanced NSCLC.
Schwartzberg LS; Li G; Tolba K; Bourla AB; Schulze K; Gadgil R; Fine A; Lofgren KT; Graf RP; Oxnard GR; Daniel D
JTO Clin Res Rep; 2022 Sep; 3(9):100386. PubMed ID: 36089920
[TBL] [Abstract][Full Text] [Related]
20. Health and Budget Impact of Liquid-Biopsy-Based Comprehensive Genomic Profile (CGP) Testing in Tissue-Limited Advanced Non-Small Cell Lung Cancer (aNSCLC) Patients.
Patel YP; Husereau D; Leighl NB; Melosky B; Nam J
Curr Oncol; 2021 Dec; 28(6):5278-5294. PubMed ID: 34940080
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
